BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38011614)

  • 1. Genetic features and outcomes of allogeneic transplantation in patients with WT1-mutated myeloid neoplasms.
    Baranwal A; Basmaci R; He R; Viswanatha D; Greipp P; Murthy HS; Foran J; Palmer J; Hogan WJ; Litzow MR; Hefazi M; Mangaonkar A; Shah MV; Al-Kali A; Alkhateeb HB
    Blood Adv; 2024 Feb; 8(3):562-570. PubMed ID: 38011614
    [No Abstract]   [Full Text] [Related]  

  • 2. Bone marrow WT1 levels in patients with myeloid neoplasms treated with 5-azacytidine: Identification of responding patients.
    Santaliestra M; Garrido A; Carricondo M; Bussaglia E; Pratcorona M; Blanco ML; Gich I; Hoyos M; Esquirol A; García-Cadenas I; Brunet S; Martino R; Sierra J; Nomdedéu JF
    Eur J Haematol; 2019 Sep; 103(3):208-214. PubMed ID: 31211880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.
    Qin YZ; Wang Y; Zhu HH; Gale RP; Zhang MJ; Jiang Q; Jiang H; Xu LP; Chen H; Zhang XH; Liu YR; Lai YY; Jiang B; Liu KY; Huang XJ
    Chin J Cancer; 2016 May; 35():46. PubMed ID: 27197573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. WT1 Measurable Residual Disease Assay in Patients With Acute Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation: Optimal Time Points, Thresholds, and Candidates.
    Cho BS; Min GJ; Park SS; Shin SH; Yahng SA; Jeon YW; Yoon JH; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Kim M; Kim Y; Kim HJ
    Biol Blood Marrow Transplant; 2019 Oct; 25(10):1925-1932. PubMed ID: 31173897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Allogeneic hematopoietic cell transplantation for myeloproliferative neoplasms].
    Takenaka K
    Rinsho Ketsueki; 2023; 64(10):1306-1313. PubMed ID: 37914246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring of minimal residual disease using WT1 assay for patients with chronic myeloid leukemia who undergo allogeneic stem cell transplantation.
    Tamaki H; Ogawa H
    Bone Marrow Transplant; 2004 Oct; 34(7):653-4. PubMed ID: 15258561
    [No Abstract]   [Full Text] [Related]  

  • 7. WT1 gene is overexpressed in myeloproliferative neoplasms, especially in myelofibrosis.
    Cottin L; Riou J; Boyer F; Bouvier A; Zannetti A; Blouet A; Truchan-Graczyk M; Jouanneau-Courville R; Beucher A; Ribourtout B; Orvain C; Hunault-Berger M; Blanchet O; Ugo V; Luque Paz D
    Blood Cells Mol Dis; 2019 Mar; 75():35-40. PubMed ID: 30612065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Utility of Wilms' Tumor 1 Monitoring in Patients with Myeloid Malignancy and Prior Allogeneic Hematopoietic Stem Cell Transplantation.
    Ino K; Fuji S; Tajima K; Tanaka T; Okinaka K; Inamoto Y; Kurosawa S; Kim SW; Katayama N; Fukuda T
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1780-1787. PubMed ID: 28673850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Allogeneic hematopoietic stem cell transplantation for myeloproliferative neoplasms].
    Takenaka K
    Rinsho Ketsueki; 2019; 60(9):1148-1156. PubMed ID: 31597838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [8p11 myeloproliferative syndrome cured by allogeneic hematopoietic stem cell transplantation: two case reports and literature review].
    Xu LP; Chen Y; Shi HX; Huang XJ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Dec; 45(6):993-6. PubMed ID: 24343089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia.
    Candoni A; Tiribelli M; Toffoletti E; Cilloni D; Chiarvesio A; Michelutti A; Simeone E; Pipan C; Saglio G; Fanin R
    Eur J Haematol; 2009 Jan; 82(1):61-8. PubMed ID: 18801058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative monitoring of WT1 expression in peripheral blood before and after allogeneic stem cell transplantation for acute myeloid leukemia - a useful tool for early detection of minimal residual disease.
    Polak J; Hajkova H; Haskovec C; Cechova H; Marinov I; Mikulenkova D; Markova J; Markova M; Vitek A; Valkova V
    Neoplasma; 2013; 60(1):74-82. PubMed ID: 23067220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of WT1 and multiparameter flow cytometry assessment in patients with chronic myelomonocytic leukemia receiving allogeneic hematopoietic stem cell transplantation.
    Pan X; Gao M; Sun Y; Zhou Y; Wang K; Wang Y; Xu L; Zhang X; Huang X; Zhao XS
    Int J Lab Hematol; 2022 Jun; 44(3):510-517. PubMed ID: 35061336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic Hematopoietic Cell Transplantation for Leukemic Transformation Preceded by Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Nationwide Survey by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.
    Takagi S; Masuoka K; Uchida N; Kurokawa M; Nakamae H; Imada K; Iwato K; Ichinohe T; Atsuta Y; Takami A; Yano S
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2208-2213. PubMed ID: 27667010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic stem cell transplantation for chronic myeloproliferative disorders and myelodysplastic syndromes: the question is "when?".
    Maziarz RT; Mesa RA; Tefferi A
    Mayo Clin Proc; 2003 Aug; 78(8):941-3. PubMed ID: 12911040
    [No Abstract]   [Full Text] [Related]  

  • 16. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia.
    Candoni A; Toffoletti E; Gallina R; Simeone E; Chiozzotto M; Volpetti S; Fanin R
    Clin Transplant; 2011; 25(2):308-16. PubMed ID: 20412098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subgroup Analysis Can Optimize the Relapse-Prediction Cutoff Value for WT1 Expression After Allogeneic Hematologic Stem Cell Transplantation in Acute Myeloid Leukemia.
    Qin YZ; Wang Y; Xu LP; Zhang XH; Zhao XS; Liu KY; Huang XJ
    J Mol Diagn; 2020 Feb; 22(2):188-195. PubMed ID: 31751675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acquired WT1 mutations contribute to relapse of NPM1-mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant.
    El Hussein S; DiNardo CD; Takahashi K; Khoury JD; Fang H; Furudate K; Lyapichev KA; Garces S; Kanagal-Shamanna R; Ok CY; Patel KP; Routbort MJ; Ravandi F; Medeiros LJ; Wang SA; Loghavi S
    Bone Marrow Transplant; 2022 Mar; 57(3):370-376. PubMed ID: 34992253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wilms' tumor gene 1 is an independent prognostic factor for pediatric acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation.
    Deng DX; Wen JJ; Cheng YF; Zhang XH; Xu LP; Wang Y; Yan CH; Chen YH; Chen H; Han W; Wang FR; Wang JZ; Qin YZ; Liu KY; Huang XJ; Zhao XS; Mo XD
    BMC Cancer; 2021 Mar; 21(1):292. PubMed ID: 33740924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Stem cells in hematology and oncology].
    Goldschmidt H; Egerer G; Fruehauf S; Ho AD
    Med Klin (Munich); 2003 Dec; 98 Suppl 2():11-4. PubMed ID: 14992195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.